EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model

Head and neck squamous cell carcinoma (HNSCC) tumours are associated with high mortality despite advances in therapy. The monoclonal antibody cetuximab (Erbitux(®)) has been approved for the treatment of advanced HNSCC. However, only a subset of HNSC patients receiving cetuximab actually responds to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gustafsson, H., Kale, A., Dasu, A., Lund, A., Edqvist, P.-H., Roberg, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691101/
https://www.ncbi.nlm.nih.gov/pubmed/28756482
http://dx.doi.org/10.1007/s12013-017-0814-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691101/
https://www.ncbi.nlm.nih.gov/pubmed/28756482
http://dx.doi.org/10.1007/s12013-017-0814-5

Ejemplares similares